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Introduction
Primary prevention of cardiovascular disease (CVD)
requires identiﬁcation of patients at high risk, and
treatment of eligible patients. To date, the Framing-
ham risk equation remains the best predictor of
cardiovascular risk, and its guidance is used to deter-
mine treatment eligibility. UK guidelines recommend:
. statins for all patients whose 10-year Framingham
CVD risk exceeds 20%
. antihypertensive treatment for all those above
this risk level whose blood pressures exceed 140/
90 mmHg
. aspirin for all those above this risk levelwho are aged
over 50 (once blood pressure has been controlled).1
EstimatingCVD risk requires clinicians to determine a
patient’s risk factor status: age, gender, diabetic status,
smoking status, blood pressure and lipid levels. How-
ever, some of these risk factors are already known. In
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Background There are many diﬀerent potential
strategies for identiﬁcation of patients eligible for
primary prevention of cardiovascular disease. The
ability to use a more eﬃcient strategy has a value.
This paper models the costs and beneﬁts of a num-
ber of identiﬁcation strategies and estimates the
additional value of an information-based strategy.
Design Modelling study.
Methods Ten-year Framingham cardiovascular
risk was calculated for each individual in a popu-
lation of 4471 persons aged 35–74 drawn from
the Health Survey for England (equivalent to a
total practice population of 12 000). Estimated
Framingham risk was calculated using limited risk
factor information and default risk factors. Costs of
risk factor assessment were calculated using stan-
dard NHS costs. The outcomes of risk factor assess-
ment were the total number of patients identiﬁed as
eligible for treatment and the total burden of
cardiovascular disease in eligible patients. Several
strategies for prioritising patients for assessment
were deﬁned: opportunistic, diabetics and treated
hypertensives ﬁrst, ranked by estimated cardio-
vascular risk. The costs and outcomes of assessing
increasing numbers of patients under each strategy
were presented in graphical form.
Results To identify 70% of the burden of cardio-
vascular disease in this population opportunistically
costs £82 102; under a ‘diabetics and hypertensives
ﬁrst’ strategy it costs £72 916; under a strategy
prioritising by estimated cardiovascular risk, £27 795.
The value of information in this scenario is there-
fore at least £45 121.
Conclusions Because strategies prioritising patients
by estimated cardiovascular risk dominate alterna-
tive strategies, it is possible to estimate the value
of information in terms of reduced resources to
achieve the same results. These resource savings
largely represent savings in staﬀ time.
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primary care, electronic medical databases have rec-
ords of every patient’s age and gender; whether a
patient is on the cardiovascular disease register is
known, diabetic status is also known, and prescribing
records are generally comprehensive. Further risk factor
information can be acquired, but at a cost. Deter-
mining a patient’s smoking status requires a clinical
consultation. Each blood pressure or cholesterol
measurement requires a clinic visit. Becausemeasured
blood pressure shows considerable variation from one
clinic visit to the next, guidelines advise clinicians to
measure blood pressure at least twice.2 Total choles-
terol and HDL cholesterol levels also show consid-
erable variation. Although previous guidance has
recommended they should be measured three times,
it is assumed that cholesterol levels are measured
twice.3 This means that estimating blood pressure
and cholesterol levels requires two clinic visits.
Assessing a patient’s CVD risk can be seen as an
investment of healthcare resources. In some patients
it is found that they are eligible for treatment, and the
investment therefore oﬀers the potential of improved
health. Because risk of CVD predicts the beneﬁts of
treatment, in those at higher risk of CVD the beneﬁt is
greater. In many the investment is not beneﬁcial
because the patient is not eligible for treatment.
A practice undertaking primary prevention of CVD
must decide on a strategy to identify patients for CVD
risk assessment. If it decides to screen all adult
patients, it makes little diﬀerence which strategy it
follows, since all patients will be assessed. However,
most practices seek to prioritise some patients for
CVD risk assessment.
Multiple risk factor measurements increase the
accuracy of estimated CVD risk, increasing the num-
ber of persons correctly identiﬁed as eligible for
treatment. This means that patients at higher CVD
risk are identiﬁed, and therefore the burden of CVD
among those identiﬁed – the sum of their CVD risks –
is higher. Multiple risk factor measurements also have
costs: clinician time, patient inconvenience and lab-
oratory costs. Data collection, therefore, has both costs
and beneﬁts. There are two sources of data available to
the practice: data collected from individual patients
when they consult; and data that has previously been
collected and is available in the primary care database.
It is well-recognised that previously collected data has
a value in describing the epidemiology and service
use associated with CVD.4 It is widely accepted that
there are considerable beneﬁts from creating pri-
mary care databases.5 However, there is little infor-
mation on the relationship between costs and beneﬁts
of data collection in primary care. This paper uses
modelling to analyse the costs and beneﬁts of using
increasing cardiovascular risk factor information to
identify patients eligible for treatments to prevent
CVD.
Methods
The model population
The study population was obtained from the Health
Survey for England of 2003.6 Patients with an existing
diagnosis of CVDwere excluded from the population,
leaving a dataset of 4471 persons aged 35–74 with
complete cardiovascular risk factor information.
Clinically measured blood pressure
and clinically measured cholesterol
level
Clinically measured blood pressure is not identical
to true mean blood pressure, and therefore diagnosis
based on the average of a number of clinically meas-
ured blood pressures is subject to a degree of mis-
classiﬁcation.7 To reﬂect chance variation in measured
blood pressure, two measured blood pressures are
generated for each individual in the model popu-
lation. The measured blood pressures are generated
using a previously describedmethodology that adjusts
the patient’s true blood pressure (the survey blood
pressure) by an error term:
Measured BP = True BP  (1 + Error Term)
A series of normally distributed error terms are
generated in Microsoft ExcelTM as random numbers
with a mean of zero and a standard deviation equal to
the coeﬃcient of variation of between-visit, measured
blood pressure. This between-visit coeﬃcient of vari-
ation is derived from meta-analysis.8
A similar process is carried out to reﬂect chance
variation in clinically measured cholesterol levels.
Two measured cholesterol levels are also generated
for each individual in the model population. These
measured cholesterol levels incorporate an error term
that is based on the coeﬃcient of variation derived
from published studies: 7.2% for total cholesterol and
7.5% for HDL cholesterol.9
Default risk factor values
When an individual’s risk factor status is not known a
best estimate of their risk factor status is substituted.
Because non-smokers outnumber smokers, individ-
uals are assumed to be non-smokers if their smoking
status is unknown. If blood pressure or cholesterol
levels are unknown, the average blood pressure or
cholesterol level for a person of their age, gender,
diabetic status and smoking status is substituted. This
follows a previously describedmethodology.10Default
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risk factor values are derived from the Health Survey
for England of 1998.11
Estimated cardiovascular risk
Data are entered into ExcelTM and individual 10-year
CVD risks are calculated for each individual using the
risk factor values in the survey and the Framingham
risk equation.12 This is taken to be each individual’s
‘gold standard’ or true 10-year CVD risk.
Five further estimates of CVD risk are calculated.
The ﬁrst estimate is based on age, gender and diabetic
status alone; the second estimate is based on age,
gender, diabetic and smoking status; the third adds
one clinically measured blood pressure measurement;
the fourth adds one clinically measured blood pres-
sure and one clinically measured cholesterol; the ﬁfth
adds two blood pressure and cholesterol measurements.
For each of these ﬁve estimates, any unmeasured risk
factors are replaced by default risk factor values.
Eligibility for treatment
Treatment eligibility criteria are determined using
the most recent UK guidelines. These recommend
antihypertensive treatment for those whose blood
pressures exceed 160/100mmHg, or with blood press-
ures exceeding 140/90 mmHg and 10-year CVD risk
over 20%.1 They also recommend aspirin for those
with more than 20% 10-year CVD risk who are aged
over 50, and statins for those with more than 20%
10-year CVD risk or with familial hyperlipidaemia
(deﬁned here as total to HDL cholesterol ratio 8).3
Treatment eligibility criteria are written as logical
functions in ExcelTM. For example, the logical func-
tion below determines whether a patient is eligible for
antihypertensive treatment (1 = eligible):
=IF(OR(‘‘SystBP’’>=160,‘‘DiastBP’’>=100),1,IF(AND
(OR(‘‘SystBP’’>=140,‘‘DiastBP’’>=90),OR(‘‘10-year
CVD Risk’’>0.2,‘‘CVD History’’=TRUE,‘‘Diabetes’’=
TRUE)),1,0))
These are then used to determine each patient’s
eligibility for treatment with aspirin, antihypertensive
or statin. Treatment eligibility status is determined
from complete risk factor data including the means of
each of two blood pressure and two cholesterol
measurements. Under some identiﬁcation strategies
not all patients undergo full risk factor assessment,
either because initial assessment suggested they are
at low risk, or because they are a low priority for
assessment. Thismeans that slightly diﬀerent numbers
of patients are identiﬁed as eligible for treatment
under diﬀerent identiﬁcation strategies.
Patient identiﬁcation strategies
Practices know the age, gender, diabetic status and
antihypertensive drug treatment status of all of their
patients. Additional risk factor data must be collected
and therefore has a cost. Information only has a value
if it inﬂuences the way in which the practice seeks to
identify patients for cardiovascular disease preven-
tion. Three diﬀerent categories of patient identiﬁ-
cation strategies are therefore modelled: full assessment
of all patients; limited assessment of all patients fol-
lowed by full assessment of a limited number; limited
assessment of all patients, using this information to
prioritise patients for full assessment.
1 Full assessment of all patients
Patients undergo full assessment on the ﬁrst occasion
that they are seen by the clinician: blood pressure and
cholesterol levels are measured at two separate clinic
visits.Within this category, the order inwhich patients
are assessed can vary. One option is to assess patients
opportunistically (in random order). A second (fol-
lowing National Service Framework recommen-
dations) is to assess diabetics on antihypertensive
treatment ﬁrst, diabetics second, those on antihyper-
tensives third, and ﬁnally all other patients.3 A third
(previously described) option is to prioritise patients
by an estimate of their 10-year CVD risk.10 This risk
estimate is calculated from their age, gender, diabetic
status and antihypertensive treatment status.
2 Limited assessment of patients followed
by full assessment of high-risk patients
Patients undergo limited risk factor assessment on the
ﬁrst occasion that they are seen. The order in which
patients undergo this limited assessment can be op-
portunistic (random), following the National Service
Framework recommendations, or by using the prior-
itisation method described above. If on ﬁrst assess-
ment a patient’s blood pressure exceeds 135/85mmHg
or their estimated 10-year CVD risk exceeds 20% or
their cholesterol exceeds 5.0mmol/l, they undergo full
risk factor assessment. This follows published rec-
ommendations.1,3 There are several variations of the
limited risk factor assessment in this strategy: in the
ﬁrst, smoking status alone is determined; in the second, a
single blood pressure is added; in the third, a single
cholesterol level is added.
3 Limited assessment of all patients
followed by full assessment of all patients
All patients undergo limited risk factor assessment.
Patients are then ranked in order of their cardiovascular
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risk and undergo full cardiovascular risk assessment in
descending risk order.
Costs
Costs are considered from the perspective of the
primary care provider. Obtaining risk factor infor-
mation on individual patients has a cost. A smoking
history requires at least one 10-minute consultation
with a practice nurse (£32 per hour): a cost of £5.33.13
Blood pressure should be measured with the patient
seated and at rest for ﬁve minutes.3 Failure to allow
suﬃcient rest period leads to systematic overestimation
of bloodpressure.14 Bloodpressuremeasurement there-
fore takes 10minutes of practice nurse time: cost £5.33.
Smokinghistory canbe ascertainedat the samevisit, and
therefore has no additional cost when blood pressure
is measured.
Cholesterol measurement takes 10 minutes of staﬀ
time plus the laboratory cost of a lipid proﬁle
(£5.67)*: a total of £11.00 if carried out by a practice
nurse. Cholesterol and blood pressure measurement
at the same visit takes 15 minutes of staﬀ time: a total
of £13.67 if carried out by a practice nurse.
In a pilot study, extracting risk factor information
from the practice database and importing into an
ExcelTM template to calculate CVD risk took two
hours of clinician time. General practitioner time
costs £118 per hour.13 This process therefore costs
£236 for a practice.
The total cost of each strategy is the sum of the costs
of any initial risk factor assessment, the costs of
ranking patients and the costs of full risk factor
assessment.
Eﬀectiveness of patient identiﬁcation
strategies
The eﬀectiveness of each patient identiﬁcation strat-
egy is ﬁrst measured as the number of patients cor-
rectly identiﬁed as eligible for treatment. Eﬀectiveness
is also measured as the total burden of CVD risk in
patients correctly identiﬁed as eligible for treatment:
this gives an indication of the total burden of prevent-
able CVD in identiﬁed patients. Because the method
by which patients are identiﬁed does not inﬂuence the
eﬀectiveness of treatments, it is not necessary to
calculate eﬀectiveness in terms of CVD prevented.
Cost-eﬀectiveness
As the resources used under any chosen strategy
increase, the number of patients identiﬁed (and the
total burden of CVD) also increases.We are interested
in the relationship between resource use and eﬀective-
ness within each strategy and how this compares
across diﬀerent strategies. The cost-eﬀectiveness of
each identiﬁcation strategy can therefore be expressed
graphically: the total cost of the strategy on the
horizontal axis and the eﬀectiveness of the strategy
on the vertical axis.
Results
In this population 1143 patients (23.6%, 95% CI:
22.4% to 24.9%) are eligible for at least one treatment:
1066 of these (93.3%, 95% CI: 91.8% to 94.8%) are
aged 45 or over. If treatment eligibility status is deter-
mined from two clinical cholesterol and two blood
pressure measurements, 25.6% (95% CI: 24.3% to
26.8%) are categorised as eligible for treatment. If all
patients are assessed in this way, clinical diagnosis
of treatment eligibility has a sensitivity of 87.8%, a
speciﬁcity of 93.7% and a positive predictive value of
81.2%.
Numbers of high-risk patients
identiﬁed
The relationship between resources allocated to
patient identiﬁcation and number of patients ident-
iﬁed as eligible for treatment is shown in Figure 1. The
equivalent relationship for burden of cardiovascular
disease is shown in Figure 2.
1 Full assessment of all patients
To identify 800 patients eligible for treatment (70% of
the total) costs £82 293 under an opportunistic strat-
egy; £75 898 under a strategy prioritising diabetics and
treated hypertensives; £42 541 under a strategy prior-
itising by cardiovascular risk. The 800 patients ident-
iﬁed have a total 10-year cardiovascular risk of 191
under an opportunistic strategy, 194 under a strategy
prioritising diabetics and treated hypertensives, and
223 under a strategy prioritising by cardiovascular
risk. These are shown as strategies 1A, 1B and 1C in
Figure 1 and Figure 2.
* Source: Reinhold Gru¨n, London School of Hygiene and
Tropical Medicine, 1996, and adjusted for inﬂation.
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Costs and sum of eligible patients with each strategy
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Figure 1 Relationship between numbers of patients identiﬁed as eligible for at least one treatment and costs
with each identiﬁcation strategy
Costs and sum of CVD risks with each strategy
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Figure 2 Relationship between burden of cardiovascular disease (sum of 10-year cardiovascular risks) in
patients identiﬁed as eligible for at least one treatment and costs with each identiﬁcation strategy
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2 Limited assessment of patients followed
by full assessment of high-risk patients
If patients are prioritised by an estimate of CVD risk, it
costs £38 218 to identify 800 patients eligible for
treatment under a strategy of only undertaking full
assessment in patients who meet certain criteria on
limited assessment. The 800 identiﬁed patients have a
total 10-year cardiovascular risk of 226. Overall the
results of this type of strategy are very similar to the
results of full assessment at ﬁrst visit. In both cases,
prioritising patients by their cardiovascular risk allows
more patients and a greater burden of cardiovascular
disease to be identiﬁed within available resources. The
curves are not included in Figure 1 and Figure 2
because they are almost indistinguishable from curves
1A, 1B and 1C.
3 Limited assessment of all patients
followed by full assessment of all patients
Strategies that collect risk factor information on all
patients and then prioritise patients for full assessment
are clearly much less eﬃcient. Before a single patient is
identiﬁed, £26 500 of staﬀ resources are needed to
ascertain smoking status, or £61 400 to check blood
pressure and cholesterol levels on all patients. These
are shown as strategies 3A and 3C in Figure 1 and
Figure 2.
The incremental value of a prioritised
prevention strategy
There are clearly very great diﬀerences in the eﬃciency
of diﬀerent strategies for identifying high-risk patients.
Strategies that advocate collecting risk factor data on
all registered patients are very ineﬃcient because
many patients do not need treatment. Strategies that
advocate opportunistic risk factor assessment, or that
use categorical variables (diabetic status, antihyper-
tensive drug treatment status) to prioritise patients
for treatment, are less eﬃcient than strategies that
prioritise patients based on an estimate of their cardio-
vascular risk.
A strategy based on estimated cardiovascular risk
requires fewer resources to identify a given burden of
preventable cardiovascular disease. We can therefore
estimate the savings that result from implementing
such a strategy. For a practice with 4471 eligible
patients (equivalent to a registered population of
12 000), to identify treatable patients with a burden
of 190 preventable cardiovascular events (70% of the
total), will cost £25 416 under a prioritised strategy,
compared with £82 102 and £72 916 under opportun-
istic or ‘diabetics and antihypertensive treatment ﬁrst’
strategies. The value of the prioritisation strategy is
therefore at least £45 121 (see Table 1).
The savings are greater in practices intending to
identifymore of their burden of cardiovascular disease
and less in those intending to identify less. However,
Table 1 Costs of identifying an equal burden of preventable CVD under diﬀerent identiﬁcation
strategies
Percentage
of total CVD
events
Total CVD
events
Strategy 1
Opportunistic
Strategy 2
Diabetics & BP
treatment ﬁrst
Strategy 3
Prioritised by
CVD risk
Value of ability
to prioritise by
CVD risk
10 27 £11 319 £3445 £2423 £1022
20 54 £22 993 £9706 £4911 £4795
30 81 £34 776 £16 185 £7919 £8267
40 108 £46 341 £28 598 £11 609 £16 988
50 135 £57 387 £43 443 £16 066 £27 377
60 162 £70 182 £58 234 £21 042 £37 192
70 190 £82 102 £72 916 £27 795 £45 121
80 217 £95 006 £87 625 £39 004 £48 621
90 244 £109 251 £104 603 £55 764 £48 839
100 271 £122 237 £122 237 £122 473 –£236
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by using the prioritised strategy, even a practice
intending to identify only 20% of its burden of
cardiovascular disease can achieve the same results
at a cost £4795 lower. Over half of the cost savings are
accounted for by a reduction in nurse time needed to
undertake risk factor assessment. The remaining
savings are accounted for by a reduced number of
lipid proﬁles.
Discussion
The method described permits analysis of the ef-
ﬁciency of several diﬀerent strategies for identifying
high-risk patients. It also demonstrates the incremen-
tal cost savings that accrue from using one strategy
rather than another. This is important as it indicates
the potential value of software and training that allows
risk factor data to be turned into information and an
identiﬁcation strategy.
The analytic method does not calculate the amount
of cardiovascular disease prevented, the number of
quality-adjusted life years gained, the costs of treat-
ment, or the costs avoided as a result of treatment in
identiﬁed patients. This analysis is unnecessary be-
cause the method by which a patient is identiﬁed is
unlikely to aﬀect the future costs or eﬀectiveness of
their treatment. Both future costs and future eﬀec-
tiveness are dependent only on the cardiovascular risk
of identiﬁed patients.15
The prioritised strategy requires only that patients’
age, gender and diabetic status are known. Clearly,
many practices have additional risk factor data on
many patients.16 A prioritised strategy is therefore
even more eﬃcient than has been illustrated here.
The analysis only includes costs from the perspec-
tive of the primary care provider. Including patient
costs – travel costs and indirect costs – increases the
cost of each clinic visit. This considerably increases the
cost per identiﬁed patient of strategies that do not
prioritise patients prior to assessment. It also ignores
additional time that might be required to counsel
patients after their cardiovascular risk has been
calculated. If this additional staﬀ time is included,
the resource savings are greater. The analysis assumes
that the costs of extracting data from the primary care
database are relatively high. However, with appropri-
ate software the costs of data extraction are negligible,
and in many practices in the UK such software
(MIQUEST17) is available. Finally, it assumes that
only nurse time is used for cardiovascular risk assess-
ment. If general practitioner time is also used for
cardiovascular risk assessment, the resource impli-
cations of ineﬃcient strategies are greater and the
savings with eﬃcient strategies considerably larger.
Conclusion
Existing data in practice databases can be used to
inform more eﬃcient strategies for identifying patients
at high risk of CVD. In eﬀect, this means that data can
be converted into knowledge. This knowledge has a
quantiﬁable value. Appropriate information tech-
nology could calculate estimated cardiovascular risks
on all patients in a practice database and identify those
most likely to beneﬁt from assessment. Such a tool
would greatly facilitate the development of registers of
high-risk patients.
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